* Evolent Health Inc EVH.N EVH is expected to show a
rise in
quarterly revenue when it reports results on August 2.
* The Arlington Virginia-based company is expected to
report a
44.0% increase in revenue to $460.701 million from $319.94
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. The company's guidance on May
3 2023, for the period ended June 30, was for revenue between
$455.00 million and $470.00 million.
* Refinitiv's mean analyst estimate for Evolent Health Inc
is for
earnings of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evolent
Health
Inc is $46, above its last closing price of $30.39.
The company's guidance on May 3 2023 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD455 million and USD49 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.21 0.20 0.21 Beat 3.7
Dec. 31 2023 0.20 0.16 0.10 Missed -39.1
Sep. 30 2022 0.13 0.12 0.59 Beat 397.6
Jun. 30 2022 0.05 0.05 0.10 Beat 105.9
Mar. 0.00 0.00 0.12 Beat 6,100
31 2022
Dec. 31 2021 0.00 0.01 0.08 Beat 860.4
Sep. 30 2021 -0.02 -0.03 -0.03 Met 8.7
Jun. 30 2021 -0.03 -0.04 -0.02 Beat 44.4
This summary was machine generated August 1 at 02:03 GMT. All
figures in US dollars unless otherwise stated